Study Results Link Postpartum Depression to Inflammation
February 25th 2020The results of a recent study published in Brain, Behavior, and Immunity suggest that inflammation and the kynurenine pathway may be connected to postpartum depression (PPD) and therefore may present new treatment targets in severe PPD.
Clinical Evidence Exists for Allopregnanolone-based Treatments
February 24th 2020With the recent approval of a Zulresso, an allopregnanolone-based treatment for postpartum depression (PPD), many pharmacists and physicians have been researching the mechanisms and other information about the drug.
Brexanolone Demonstrates More Change from Baseline Compared with SSRIs
February 19th 2020The results of a systematic literature review published in CNS Drugs suggested that brexanolone injection, the first therapy approved by the FDA for the treatment of postpartum depression, is more effective than selective serotonin reuptake inhibitors in the treatment of women suffering from postpartum depression.
Dolutegravir Is Susceptible to Chelation-Type Interactions
Common medications containing polyvalent cations should be separated to prevent decreased absorption of the HIV therapy.